Merck’s Keytruda scores key NICE sign-off for first-line NSCLC indicationnews2022-01-07T15:02:47+00:00January 7th, 2022|Fierce Pharma|
FDA must hit the gas on FOIA request tied to Pfizer’s COVID-19 vaccine, judge ordersnews2022-01-07T14:23:09+00:00January 7th, 2022|Fierce Pharma|
Say what you see: Novavax taps its own branding for latest COVID vaccinenews2022-01-07T14:15:05+00:00January 7th, 2022|Fierce Pharma|
Regeneron hands over Evkeeza rights to Ultragenyx outside US, with an R&D asset also thrown innews2022-01-07T13:55:25+00:00January 7th, 2022|Fierce Pharma|
Fierce Pharma Asia—Samsung and Biogen rumors; Novartis-BeiGene TIGIT deal; Aduhelm’s Japan defeatnews2022-01-07T11:24:05+00:00January 7th, 2022|Fierce Pharma|
Blueprint’s Ayvakit launch ramps up as it taps LabCorp, new education campaign to boost awarenessnews2022-01-07T10:27:07+00:00January 7th, 2022|Fierce Pharma|
Viatris shareholders rail against execs’ hefty pay packagesnews2022-01-06T21:03:53+00:00January 6th, 2022|Fierce Pharma|
Teva, Sandoz have launched Narcan generics, but Emergent’s branded option should still thrive: analystsnews2022-01-06T16:37:11+00:00January 6th, 2022|Fierce Pharma|
Biogen’s Aduhelm faces a key coverage decision next week. Which way will Medicare rule, and how much does it matter?news2022-01-06T16:26:29+00:00January 6th, 2022|Fierce Pharma|
With dual approvals, Biohaven’s migraine blockbuster-in-waiting snares nearly $500M in 2021news2022-01-06T16:17:44+00:00January 6th, 2022|Fierce Pharma|
